Limits...
DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition.

Wu X, Zhao Z, Bai H, Fu T, Yang C, Hu X, Liu Q, Champanhac C, Teng IT, Ye M, Tan W - Theranostics (2015)

Bottom Line: In this work, we have developed a truncated DNA aptamer, termed XQ-2d, with high affinity and specificity for pancreatic ductal adenocarcinoma (PDAC).Moreover, XQ-2d shows better recognition ratio for 40 tissue sections of clinical PDAC samples (82.5%) compared to the initial cell-SELEX selection library (5%).Therefore, XQ-2d can be considered a promising candidate as a tool for PDAC diagnosis and treatment.

View Article: PubMed Central - PubMed

Affiliation: 1. Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha 410082, China.

ABSTRACT
In this work, we have developed a truncated DNA aptamer, termed XQ-2d, with high affinity and specificity for pancreatic ductal adenocarcinoma (PDAC). Aptamer XQ-2d selectively binds to PL45 cells with a dissociation constant in the nanomolar range, as determined by its recognition of PL45 tumor cells in mice. Moreover, XQ-2d shows better recognition ratio for 40 tissue sections of clinical PDAC samples (82.5%) compared to the initial cell-SELEX selection library (5%). Therefore, XQ-2d can be considered a promising candidate as a tool for PDAC diagnosis and treatment.

No MeSH data available.


Related in: MedlinePlus

Binding ability of aptamer XQ-2 (250 nM, red line) on different cell lines. The unselected initial library (250 nM, black line) was used as control.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4493536&req=5

Figure 4: Binding ability of aptamer XQ-2 (250 nM, red line) on different cell lines. The unselected initial library (250 nM, black line) was used as control.

Mentions: To test the binding ability of aptamer XQ-2 for other cell lines, 14 cell lines, including 12 cancer cell lines and 2 normal cell lines, were incubated with 250 nM of FAM-labeled aptamers at 4 °C for 1 h, respectively. As shown in Figure 4, aptamer XQ-2 strongly bound three leukemia cell lines (HL60, CCRF-CEM, and Ramos), prostate cancer DU145 cell line, gastric cancer MGC-803 cells, breast cancer MDA-MB-231 cell line and two lung cancer cell lines (95-C and H1299). However, it showed little binding affinity for four other cancer cell lines, including breast cancer MCF-7, lung cancer 95-D, colon carcinoma HCT116 and human melanoma SK23 cells, when compared with FAM-labeled library. Moreover, aptamer XQ-2 showed no binding ability to two other normal cell lines: primary fibroblast MRC5 and human embryonic kidney epithelial HEK293. These results indicate that the target of aptamer XQ-2 is highly expressed in HL60, CCRF-CEM, Ramos, DU145, MGC-803, MDA-MB-231, 95-C and H1299 cancer cell lines, but little in MCF-7, 95-D, HCT116 and SK23 cancer cell lines. It could therefore be expected that the selected aptamer XQ-2 could be used as molecular probe for recognizing some kinds of cancer cells, as well as differentiating their subtypes.


DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition.

Wu X, Zhao Z, Bai H, Fu T, Yang C, Hu X, Liu Q, Champanhac C, Teng IT, Ye M, Tan W - Theranostics (2015)

Binding ability of aptamer XQ-2 (250 nM, red line) on different cell lines. The unselected initial library (250 nM, black line) was used as control.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4493536&req=5

Figure 4: Binding ability of aptamer XQ-2 (250 nM, red line) on different cell lines. The unselected initial library (250 nM, black line) was used as control.
Mentions: To test the binding ability of aptamer XQ-2 for other cell lines, 14 cell lines, including 12 cancer cell lines and 2 normal cell lines, were incubated with 250 nM of FAM-labeled aptamers at 4 °C for 1 h, respectively. As shown in Figure 4, aptamer XQ-2 strongly bound three leukemia cell lines (HL60, CCRF-CEM, and Ramos), prostate cancer DU145 cell line, gastric cancer MGC-803 cells, breast cancer MDA-MB-231 cell line and two lung cancer cell lines (95-C and H1299). However, it showed little binding affinity for four other cancer cell lines, including breast cancer MCF-7, lung cancer 95-D, colon carcinoma HCT116 and human melanoma SK23 cells, when compared with FAM-labeled library. Moreover, aptamer XQ-2 showed no binding ability to two other normal cell lines: primary fibroblast MRC5 and human embryonic kidney epithelial HEK293. These results indicate that the target of aptamer XQ-2 is highly expressed in HL60, CCRF-CEM, Ramos, DU145, MGC-803, MDA-MB-231, 95-C and H1299 cancer cell lines, but little in MCF-7, 95-D, HCT116 and SK23 cancer cell lines. It could therefore be expected that the selected aptamer XQ-2 could be used as molecular probe for recognizing some kinds of cancer cells, as well as differentiating their subtypes.

Bottom Line: In this work, we have developed a truncated DNA aptamer, termed XQ-2d, with high affinity and specificity for pancreatic ductal adenocarcinoma (PDAC).Moreover, XQ-2d shows better recognition ratio for 40 tissue sections of clinical PDAC samples (82.5%) compared to the initial cell-SELEX selection library (5%).Therefore, XQ-2d can be considered a promising candidate as a tool for PDAC diagnosis and treatment.

View Article: PubMed Central - PubMed

Affiliation: 1. Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha 410082, China.

ABSTRACT
In this work, we have developed a truncated DNA aptamer, termed XQ-2d, with high affinity and specificity for pancreatic ductal adenocarcinoma (PDAC). Aptamer XQ-2d selectively binds to PL45 cells with a dissociation constant in the nanomolar range, as determined by its recognition of PL45 tumor cells in mice. Moreover, XQ-2d shows better recognition ratio for 40 tissue sections of clinical PDAC samples (82.5%) compared to the initial cell-SELEX selection library (5%). Therefore, XQ-2d can be considered a promising candidate as a tool for PDAC diagnosis and treatment.

No MeSH data available.


Related in: MedlinePlus